ロード中...
Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity
BACKGROUND: Bortezomib (Bz) is a proteasome inhibitor that directly targets antibody-producing plasma cells. We recently reported the first randomized control trial that evaluated the effects of Bz in patients with systemic lupus erythematosus (SLE). In that study, we demonstrated that Bz treatment...
保存先:
| 出版年: | Arthritis Res Ther |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5553803/ https://ncbi.nlm.nih.gov/pubmed/28800777 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-017-1397-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|